Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury

NCT01484184 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Spinal Cord Injury

Interventions

DRUG: SPINALON (buspirone + levodopa + cardidopa)

Sponsor

Nordic Life Science Pipeline Inc.

Collaborators

[object Object]